轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02575 轩竹生物-B

未开盘 10-23 16:08:09

8.250

-0.050

-0.60%

最高8.515	最低8.100	成交量75.30万
今开8.300	昨收8.300	日振幅5.00%
总市值42.74亿	流通市值42.73亿	总股本5.18亿
成交额622.94万	换手率0.15%	流通股本5.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":8.25,"timestamp":1792742889007,"preClose":8.3,"halted":0,"volume":753000,"delay":0,"changeRate":-0.006024096385542254,"floatShares":517947790,"shares":518000000,"eps":-0.53,"marketStatus":"未开盘","change":-0.05,"latestTime":"10-23 16:08:09","open":8.3,"high":8.515,"low":8.1,"amount":6229360,"amplitude":0.05,"askPrice":8.3,"askSize":14000,"bidPrice":8.25,"bidSize":20500,"shortable":3,"etf":0,"ttmEps":-0.486212,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":8.3,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":0.4596788962766659,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575","defaultTab":"news","newsList":[{"id":"2677674522","title":"轩竹生物-B(02575.HK)：安奈拉唑钠治疗反流性食管炎III期临床研究数据于 UEG Week 2026展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2677674522","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677674522?lang=zh_cn&edition=full","pubTime":"2026-10-21 21:00","pubTimestamp":1792587628,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183773880","title":"轩竹生物-B（02575）披露安奈拉唑钠治疗反流性食管炎III期试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1183773880","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183773880?lang=zh_cn&edition=full","pubTime":"2026-10-21 20:55","pubTimestamp":1792587331,"startTime":"0","endTime":"0","summary":"2026年10月21日，轩竹生物科技股份有限公司发布自愿公告称，其自主研发的国家1类创新药安奈拉唑钠肠溶片用于反流性食管炎的III期注册临床研究结果，已在西班牙巴塞罗那举行的第34届欧洲消化疾病周以Late-Breaking Abstract口头报告形式公布。公司表示，发布上述数据旨在向投资者通报最新业务进展，不构成对任何药物或治疗的宣传。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189467280","title":"轩竹生物-B 9月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1189467280","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189467280?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:41","pubTimestamp":1791373262,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司于2026年10月7日发布截至2026年9月30日止的证券变动月报。报告期内，公司普通股H股的已发行股份数与注册股本均维持在517,947,790股，面值为人民币1元，注册股本为人民币517,947,790元，与上月无变化。根据公告，9月间公司无新增发行、购回、注销或库藏股等股份变动；并未披露任何有关股份期权计划以及可换股票据或其他协议的变动信息。公司方面表示，将继续遵守相关监管规定。该公告由联席公司秘书何成明签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671936102","title":"港股异动 | 轩竹生物-B(02575)午后飙升20% 公司此前宣布初步讨论一项潜在的收购事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2671936102","media":"智通财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671936102?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:37","pubTimestamp":1790660259,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B午后飙升20%。截至发稿，涨19.75%，报9.7港元，成交额4847.58万港元。消息面上，轩竹生物9月17日股价一度大幅飙升40%，公司当日盘后发布股价异常波动自愿公告，披露现正与某方就一项潜在的收购事项进行初步讨论，相关磋商仍在推进。有关潜在收购事项之条款及条件尚未落实，集团截至公告日期并未就潜在收购事项订立正式协议。概不保证潜在收购事项将会落实或最终完成，该交易未必会开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02575","BK1191","KCAI","BK4588","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668985919","title":"港股异动 | 轩竹生物-B(02575.HK)早盘涨超7% 公司发布澄清公告 透露正在磋商潜在收购事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2668985919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668985919?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:14","pubTimestamp":1789697652,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964385","title":"轩竹生物-B(02575)：股价异常波动 正与某方就一项潜在收购事项进行初步讨论","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964385","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668964385?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:49","pubTimestamp":1789645743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，公司董事会注意到，公司H股价格于今日有所上升。董事会谨此知会，公司现正与某方就一项潜在收购事项进行初步讨论。于本公告日期，磋商仍在进行中。有关潜在收购事项的条款及条件尚未落实，而集团于截至本公告日期并无就潜在收购事项订立正式协议。概不保证潜在收购事项将会落实或最终完成。公司将适时遵守香港联合交易所有限公司证券上市规则第14章及第14A章的相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123471117","title":"轩竹生物-B（02575）发布自愿性公告：称不知股价上升原因 正就潜在收购事项进行初步讨论","url":"https://stock-news.laohu8.com/highlight/detail?id=1123471117","media":"公告速递","labels":["merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123471117?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:45","pubTimestamp":1789645531,"startTime":"0","endTime":"0","summary":"2026年9月17日，轩竹生物科技股份有限公司披露自愿性公告，回应当日H股价格出现上升的情况。公司董事会表示，已就有关价格变化作出合理查询，确认并不知悉导致股价波动的任何原因，也不存在须予披露的内幕消息或需要根据香港《证券及期货条例》第XIVA部披露的信息。董事会提醒股东及潜在投资者在买卖公司H股时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668956052","title":"港股异动 | 轩竹生物-B午后升逾20%，与泰国Innobic就吡洛西利片签署三方商业协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2668956052","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668956052?lang=zh_cn&edition=full","pubTime":"2026-09-17 14:13","pubTimestamp":1789625620,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B午后拉升逾40%，截至发稿，涨34.69%，报10.95港元，成交额9289.93万港元。消息面上，轩竹生物-B发布公告，集团与泰国制药公司Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd就集团的吡洛西利片签署三方商业协议，协议期限至2036年6月30日届满。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场行销及商业化运营。","market":"sh","thumbnail":"https://community-static.tradeup.com/news/c93b077b110748a8ecb15e18acfb6521","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c93b077b110748a8ecb15e18acfb6521"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497281.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","KCAI","VXUS","BK4585","BK1191","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1188191478","title":"轩竹生物-B2025年度治理强化：聚焦控股股东关系与独立审阅机制","url":"https://stock-news.laohu8.com/highlight/detail?id=1188191478","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188191478?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:34","pubTimestamp":1789562093,"startTime":"0","endTime":"0","summary":"轩竹生物-B于2025年度的公司报告显示，集团在公司治理层面重点加强与控股股东之间的利益冲突管控，并通过独立董事年度审阅与信息披露制度，致力于保障少数股东的合法权益。该等措施源于招股章程中对企业管治的相关要求，强调独立非执行董事对可能存在利益冲突的事项及双方日常交易进行评估，确保交易按照正常商业条款并符合相关上市规则。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"轩竹生物-B2025年度治理强化：聚焦控股股东关系与独立审阅机制","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119683249","title":"轩竹生物-B上半年营收69.4百万元（同比增长288.1%），经调整净亏损75.3百万元（收窄32.1%）","url":"https://stock-news.laohu8.com/highlight/detail?id=1119683249","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119683249?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:44","pubTimestamp":1789548263,"startTime":"0","endTime":"0","summary":"轩竹生物-B发布的2026年中期业绩显示，截至2026年6月30日止六个月，营收约为69.4百万元，同比大幅增加288.1%。报告期内，经调整净亏损约为75.3百万元，同比收窄32.1%。报告期内，本集团在经营方面的费用表现显示了管理层对成本结构的持续精细化控制：本期经营开支约为93.4百万元，较上年同期减少22.2%；其中研发开支同比减少67.1%，销售及分销开支的增加主要系核心新药上市后的市场拓展投入所致，行政开支也有所减少。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B上半年营收69.4百万元（同比增长288.1%），经调整净亏损75.3百万元（收窄32.1%）","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164847772","title":"轩竹生物-B8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1164847772","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164847772?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:05","pubTimestamp":1788519951,"startTime":"0","endTime":"0","summary":"2026年9月4日，轩竹生物科技股份有限公司发布截至2026年8月31日的证券变动月报表。报告期内，公司已发行普通股为H股，注册股本人民币517,947,790元，股本未发生任何变动，保持在517,947,790股。公司确认于本月未进行任何新增发行、购回、注销或库藏股相关活动。根据香港联交所上市规则，公司H股已维持符合最低公众持股量要求。公司同时声明，已遵守香港联交所《上市规则》及相关法律法规，现有股本状况整体稳定，后续如有进展将及时披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386607","title":"港股异动 | 四环医药(00460)午前涨近4% 轩竹生物与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664386607?lang=zh_cn&edition=full","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","KCAI","02575","BK1515","BK1600","BK4585","BK1191","BK1593","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158047728","title":"轩竹生物-B（02575）与Innobic签署吡洛西利片泰国独家商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1158047728","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158047728?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:21","pubTimestamp":1788427273,"startTime":"0","endTime":"0","summary":"2026年9月3日，轩竹生物科技股份有限公司发布自愿性公告称，其已与Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd签订关于吡洛西利片的三方商业协议，协议有效期至2036年6月30日。根据协议，轩竹生物-B授予Innobic（亚洲）与早安国际在泰国的独家商业化权利，涵盖进口、推广、营销、要约销售、销售及经销等活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878545","title":"轩竹生物-B(02575)与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878545","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664878545?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:15","pubTimestamp":1788426905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，集团于近日与泰国制药公司Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd就集团的吡洛西利片签署三方商业协议，协议期限至2036年6月30日届满。根据该协议，集团向Innobic(亚洲)及早安国际共同授予目标产品于泰国区域内的独家商业化权利，该等商业化权利包括在目标区域内进口、推广、营销、要约销售、销售及经销目标产品的权利。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场行销及商业化运营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664785438","title":"轩竹生物-B(02575.HK)与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664785438","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664785438?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:15","pubTimestamp":1788426905,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124650509","title":"轩竹生物-B：授予Innobic（亚洲）与兆安国际在泰国的Birecociclib独家商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1124650509","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124650509?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:14","pubTimestamp":1788426853,"startTime":"0","endTime":"0","summary":"轩竹生物-B宣布，已向Innobic（亚洲）及兆安国际授予其产品Birecociclib在泰国的独家商业化权利。此举标志着该公司在拓展东南亚市场方面迈出了重要一步。Birecociclib作为轩竹生物的核心在研产品之一，其海外授权合作备受业界关注。此次协议的签署，不仅体现了轩竹生物对合作伙伴实力的认可，也展现了其全球化战略的坚定决心。通过携手Innobic（亚洲）与兆安国际这两家深耕亚洲市场的企业，轩竹生物旨在加速该药物在泰国市场的落地与推广。未来，随着合作的深入，Birecociclib有望为泰国患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104776053","title":"轩竹生物-B宣布与Innobic达成泰国市场Birecociclib商业合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1104776053","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104776053?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:14","pubTimestamp":1788426851,"startTime":"0","endTime":"0","summary":"轩竹生物-B正式对外披露，已同Innobic就Birecociclib在泰国境内的商业化推广签署合作协议。此举意味着该药物在东南亚市场的布局迈出关键一步。双方将依托各自优势，共同推进产品在泰国的落地与销售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382922","title":"轩竹生物-B（02575）午后大涨25% 上半年收入同比大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382922","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664382922?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:59","pubTimestamp":1788415158,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物-B（02575）午后股价大幅拉升，并曾触发市调机制进入冷静期，截至发稿，报11.78港元，涨25.25%，成交额7051.21万港元。消息面上，公司上半年取得收入6940万元人民币，同比增加288.1%。收入增长主要因新产品上市及纳入国家基本医保药品目录而带动销量增长所致。公司经营开支约为人民币9340万元，同比减少约22.2%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990570","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664829917","title":"港股异动 | 轩竹生物-B(02575.HK)午后飙升逾40% 上半年收入同比激增近三倍 今年为轩悦宁完整放量元年","url":"https://stock-news.laohu8.com/highlight/detail?id=2664829917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664829917?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:37","pubTimestamp":1788413841,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664982596","title":"港股异动 | 轩竹生物-B(02575)午前涨超5% 中期收入同比增加288.1% 对外授权与许可引进双向发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2664982596","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664982596?lang=zh_cn&edition=full","pubTime":"2026-09-03 11:37","pubTimestamp":1788406643,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B午前涨超5%，截至发稿，涨5.42%，报9.915港元，成交额277.97万港元。消息面上，轩竹生物-B发布截至2026年6月30日止6个月业绩，该集团期内取得收入6940万元人民币，同比增加288.1%。公告称，收入增长主要因新产品上市及纳入国家基本医保药品目录而带动销量增长所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","KCAI","BK1191","BK4588","02575"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0401},{"period":"3month","weight":-0.2973},{"period":"6month","weight":-0.6676},{"period":"1year","weight":-0.8613},{"period":"ytd","weight":-0.883}],"compareEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.0701},{"period":"3month","weight":-0.0749},{"period":"6month","weight":-0.111},{"period":"1year","weight":-0.1107},{"period":"ytd","weight":-0.099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。","exchange":"SEHK","name":"轩竹生物-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"轩竹生物-B,02575,轩竹生物-B股票,轩竹生物-B股票老虎,轩竹生物-B股票老虎国际,轩竹生物-B行情,轩竹生物-B股票行情,轩竹生物-B股价,轩竹生物-B股市,轩竹生物-B股票价格,轩竹生物-B股票交易,轩竹生物-B股票购买,轩竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}